Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination

Vaccine

Volumn 27, Issue 39, 2009, Pages 5393-5401

  Zinckgraf, John W ^a   Sposato, Margaret ^a   Zielinski, Veronica ^a   Powell, Doug ^a   Treanor, John J ^b   von Hofe, Eric ^a  

^a Antigen Express Inc   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

CD4; Epitope; H5N1; T helper cells; Vaccine

Indexed keywords

HEMAGGLUTININ; HLA ANTIGEN CLASS 2; INFLUENZA A H5N1 HA PEPTIDE VACCINE; INFLUENZA A H5N1 VACCINE; INFLUENZA VACCINE; PEPTIDE VACCINE; RECOMBINANT H5N1 HEMAGGLUTININ; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMORAL IMMUNITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ALGORITHMS; CD4-POSITIVE T-LYMPHOCYTES; HEMAGGLUTININS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNODOMINANT EPITOPES; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; INTERFERON-GAMMA; MIDDLE AGED; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 68349114866     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.06.081     Document Type: Article

References (42)

1. Fauci A.S. Emerging and re-emerging infectious diseases: influenza as a prototype of the host-pathogen balancing act. Cell 124 (2006) 665
2. Monto A.S., and Whitley R.J. Seasonal and pandemic influenza: a 2007 update on challenges and solutions. Clin Infect Dis 46 (2008) 1024
3. Taubenberger J.K., Morens D.M., and Fauci A.S. The next influenza pandemic: can it be predicted?. JAMA 297 (2007) 2025
4. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., and Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354 (2006) 1343
5. Zangwill K.M., Treanor J.J., Campbell J.D., Noah D.L., and Ryea J. Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. J Infect Dis 197 (2008) 580
6. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367 (2006) 1657
7. Lin J., Zhang J., Dong X., Fang H., Chen J., Su N., et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368 (2006) 991
8. Leroux-Roels I., Borkowski A., Vanwolleghem T., Drame M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370 (2007) 580
9. Mozdzanowska K., Furchner M., Maiese K., and Gerhard W. CD4+ T cells are ineffective in clearing a pulmonary infection with influenza type A virus in the absence of B cells. Virology 239 (1997) 217
10. Mozdzanowska K., Furchner M., Zharikova D., Feng J., and Gerhard W. Roles of CD4+ T-cell-independent and -dependent antibody responses in the control of influenza virus infection: evidence for noncognate CD4+ T-cell activities that enhance the therapeutic activity of antiviral antibodies. J Virol 79 (2005) 5943
11. Topham D.J., Tripp R.A., and Doherty P.C. CD8+ T cells clear influenza virus by perforin or Fas-dependent processes. J Immunol 159 (1997) 5197
12. Brown D.M., Roman E., and Swain S.L. CD4 T cell responses to influenza infection. Semin Immunol 16 (2004) 171
13. Swain S.L., Agrewala J.N., Brown D.M., Jelley-Gibbs D.M., Golech S., Huston G., et al. CD4+ T-cell memory: generation and multi-faceted roles for CD4+ T cells in protective immunity to influenza. Immunol Rev 211 (2006) 8
14. Hogan R.J., Zhong W., Usherwood E.J., Cookenham T., Roberts A.D., and Woodland D.L. Protection from respiratory virus infections can be mediated by antigen-specific CD4(+) T cells that persist in the lungs. J Exp Med 193 (2001) 981
15. Paludan C., Bickham K., Nikiforow S., Tsang M.L., Goodman K., Hanekom W.A., et al. Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt's lymphoma cells. J Immunol 169 (2002) 1593
16. Graham M.B., Braciale V.L., and Braciale T.J. Influenza virus-specific CD4+ T helper type 2 T lymphocytes do not promote recovery from experimental virus infection. J Exp Med 180 (1994) 1273
17. Graham M.B., and Braciale T.J. Resistance to and recovery from lethal influenza virus infection in B lymphocyte-deficient mice. J Exp Med 186 (1997) 2063
18. Mozdzanowska K., Maiese K., and Gerhard W. Th cell-deficient mice control influenza virus infection more effectively than Th- and B cell-deficient mice: evidence for a Th-independent contribution by B cells to virus clearance. J Immunol 164 (2000) 2635
19. Gerhard W. The role of the antibody response in influenza virus infection. Curr Top Microbiol Immunol 260 (2001) 171
20. Levi R., and Arnon R. Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection. Vaccine 14 (1996) 85
21. Bot A., Bot S., Antohi S., Karjalainen K., and Bona C. Kinetics of generation and persistence on membrane class II molecules of a viral peptide expressed on foreign and self proteins. J Immunol 157 (1996) 3436
22. Adams S., and Humphreys R.E. Invariant chain peptides enhancing or inhibiting the presentation of antigenic peptides by major histocompatibility complex class II molecules. Eur J Immunol 25 (1995) 1693
23. Kallinteris N.L., Lu X., Wu S., Hu H., Li Y., Gulfo J.V., et al. Ii-Key/MHC class II epitope hybrid peptide vaccines for HIV. Vaccine 21 (2003) 4128
24. Kallinteris N.L., Wu S., Lu X., Humphreys R.E., von Hofe E., and Xu M. Enhanced CD4+ T-cell response in DR4-transgenic mice to a hybrid peptide linking the Ii-Key segment of the invariant chain to the melanoma gp100(48-58) MHC class II epitope. J Immunother 28 (2005) 352
25. Kallinteris N.L., Powell D., Blackwell C.E., Kim M., Lu X., Wu S., et al. Ii-Key/MHC class II epitope peptides as helper T cell vaccines for cancer and infectious disease. Front Biosci (2006) 46
26. Gillogly M.E., Kallinteris N.L., Xu M., Gulfo J.V., Humphreys R.E., and Murray J.L. Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer. Cancer Immunol Immunother 53 (2004) 490
27. Holmes J.P., Benavides L.C., Gates J.D., Carmichael M.G., Hueman M.T., Mittendorf E.A., et al. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol 26 (2008) 3426
28. Hosmalin A., Nara P.L., Zweig M., Lerche N.W., Cease K.B., Gard E.A., et al. Priming with T helper cell epitope peptides enhances the antibody response to the envelope glycoprotein of HIV-1 in primates. J Immunol 146 (1991) 1667
29. Kaufmann D.E., Bailey P.M., Sidney J., Wagner B., Norris P.J., Johnston M.N., et al. Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. J Virol 78 (2004) 4463
30. Sotiriadou N.N., Kallinteris N.L., Gritzapis A.D., Voutsas I.F., Papamichail M., von Hofe E., et al. Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors. Cancer Immunol Immunother 56 (2007) 601
31. Roti M., Yang J., Berger D., Huston L., James E.A., and Kwok W.W. Healthy human subjects have CD4+ T cells directed against H5N1 influenza virus. J Immunol 180 (2008) 1758
32. Lindemann M., Witzke O., Lutkes P., Fiedler M., Kreuzfelder E., Philipp T., et al. ELISpot assay as a sensitive tool to detect cellular immunity following influenza vaccination in kidney transplant recipients. Clin Immunol 120 (2006) 342
33. Mwau M., McMichael A.J., and Hanke T. Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines. AIDS Res Hum Retroviruses 18 (2002) 611
34. Gelder C.M., Welsh K.I., Faith A., Lamb J.R., and Askonas B.A. Human CD4+ T-cell repertoire of responses to influenza A virus hemagglutinin after recent natural infection. J Virol 69 (1995) 7497
35. Richards K.A., Chaves F.A., Krafcik F.R., Topham D.J., Lazarski C.A., and Sant A.J. Direct ex vivo analyses of HLA-DR1 transgenic mice reveal an exceptionally broad pattern of immunodominance in the primary HLA-DR1-restricted CD4 T-cell response to influenza virus hemagglutinin. J Virol 81 (2007) 7608
36. Zhong W., Marshall D., Coleclough C., and Woodland D.L. CD4+ T cell priming accelerates the clearance of Sendai virus in mice, but has a negative effect on CD8+ T cell memory. J Immunol 164 (2000) 3274
37. Crowe S.R., Miller S.C., Brown D.M., Adams P.S., Dutton R.W., Harmsen A.G., et al. Uneven distribution of MHC class II epitopes within the influenza virus. Vaccine 24 (2006) 457
38. Gelder C.M., Lamb J.R., and Askonas B.A. Human CD4+ T-cell recognition of influenza A virus hemagglutinin after subunit vaccination. J Virol 70 (1996) 4787
39. Danke N.A., and Kwok W.W. HLA class II-restricted CD4+ T cell responses directed against influenza viral antigens postinfluenza vaccination. J Immunol 171 (2003) 3163
40. Novak E.J., Liu A.W., Nepom G.T., and Kwok W.W. MHC class II tetramers identify peptide-specific human CD4(+) T cells proliferating in response to influenza A antigen. J Clin Invest 104 (1999) R63
41. Kallinteris N.L., Wu S., Lu X., Humphreys R.E., von Hofe E., and Xu M. Enhanced CD4+ T cell response in DR4-transgenic mice to a hybrid peptide linking the Ii-Key segment of the invariant chain to the melanoma gp100(46-58) MHC class II epitope. J Immunother 28 (2005) 352
42. Brown D.M., Dilzer A.M., Meents D.L., and Swain S.L. CD4 T cell-mediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one-two punch. J Immunol 177 (2006) 2888